Different subtypes of CAFs display specific functions in tumor pathogenesis and various CAF markers suggest potential treatment targets, such as FAP and GPR77. Stable cancer-associated fibroblasts (CAFs) are important cellular components in the ovarian cancer tumor microenvironment and may provide novel resources for future treatment strategies. Ovarian cancer is a lethal gynecologic tumor and is generally resistant to conventional treatments.
Intergroupe Francophone de Cancérologie Thoracique (IFCT).
#Nvalt and concept maps plus#
We noted more grade 3 or higher hypertension (51 of 222 vs 0) and thrombotic events (13 of 222 vs 2 of 224) with PCB than with PC.Īddition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
#Nvalt and concept maps Pc#
Overall, 158 (71%) of 222 patients given PCB and 139 (62%) of 224 patients given PC had grade 3-4 adverse events. OS was significantly longer with PCB (median 18♸ months ) than with PC (16♱ months hazard ratio 0♷7 p=0♰167).
#Nvalt and concept maps trial#
This IFCT-GFPC-0701 trial is registered with, number NCT00651456.įrom Feb 13, 2008, to Jan 5, 2014, we randomly assigned 448 patients to treatment (223 to PCB and 225 to PC).
The primary outcome was overall survival (OS) in the intention-to treat population. We randomly allocated patients (1:1 minimisation method used patients stratified by histology, performance status score, study centre, or smoking status ) to receive intravenously 500 mg/m(2) pemetrexed plus 75 mg/m(2) cisplatin with (PCB) or without (PC) 15 mg/kg bevacizumab in 21 day cycles for up to six cycles, until progression or toxic effects. Exclusion criteria were presence of central nervous system metastases, use of antiaggregant treatments (aspirin ≥325 mg per day, clopidogrel, ticlopidine, or dipyridamole), anti-vitamin K drugs at a curative dose, treatment with low-molecular-weight heparin at a curative dose, and treatment with non-steroidal anti-inflammatory drugs. In this randomised, controlled, open-label, phase 3 trial, we recruited patients aged 18-75 years with unresectable malignant pleural mesothelioma who had not received previous chemotherapy, had an Eastern Cooperative Oncology Group performance status of 0-2, had no substantial cardiovascular comorbidity, were not amenable to curative surgery, had at least one evaluable (pleural effusion) or measurable (pleural tumour solid thickening) lesion with CT, and a life expectancy of >12 weeks from 73 hospitals in France.
We aimed to assess the effect on survival of bevacizumab when added to the present standard of care, cisplatin plus pemetrexed, as first-line treatment of advanced malignant pleural mesothelioma. Vascular endothelial growth factor is a key mitogen for malignant pleural mesothelioma cells, therefore targeting of vascular endothelial growth factor might prove effective. Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure.
0 kommentar(er)
